Skip to main content
Premium Trial:

Request an Annual Quote

Agilent's Fiscal Q4 Revenues Rise 6 Percent; Bio-Analytical Measurement Grows 9 Percent

NEW YORK (GenomeWeb News) — Agilent Technologies today said fiscal fourth-quarter revenues increased 6 percent as R&D spending fell 8 percent and profit surged 508 percent.
Total receipts for the three months ended Sept. 30 increased to $1.33 billion from $1.25 billion year over year.
Revenue for the company’s Bio-Analytical Measurement segment rose 9 percent to $418 million.
R&D spending decreased to $155 million from $168 million year over year.
The company said profit increased to $152 million from $25 million in the year-ago period, which included restructuring charges and other items.
Agilent said it had around $2.3 billion in cash and equivalents as of Sept. 30.
During the quarter, Agilent said its return on invested capital was at 29 percent, and the company issued a two-year, $2-billion stock repurchase program
The company said it expects fiscal first-quarter 2007 revenues to be between $1.25 billion and $1.29 billion, or between 7 percent and 10 percent better than the same quarter of 2006.

The Scan

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.

Study Reviews Family, Provider Responses to Rapid Whole-Genome Sequencing Follow-up

Investigators identified in the European Journal of Human Genetics variable follow-up practices after rapid whole-genome sequencing.

BMI-Related Variants Show Age-Related Stability in UK Biobank Participants

Researchers followed body mass index variant stability with genomic structural equation modeling and genome-wide association studies of 40- to 72-year olds in PLOS Genetics.

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.